Myeloma UK: Emerging treatments
Publicado: Lun Nov 30, 2015 7:49 pm
Myeloma UK: Emerging treatments
Expert Rev Anticancer Ther. 2015 Nov 20. [Epub ahead of print]
Oral Ixazomib Maintenance Therapy in Multiple Myeloma.
Offidani M1, Corvatta L2, Gentili S1, Maracci L1, Leoni P1.
http://www.ncbi.nlm.nih.gov/pubmed/26588946
Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13799. [Epub ahead of print]
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E1,2, Gatt ME3, Rouvio O4, Ganzel C5, Chubar E6, Suriu C7, Tadmor T8, Shevetz O9, Lavi N10, Shochat T11, Cohen YC2,12, Avivi I2,12, Raanani P1,2, Magen H1,2.
http://www.ncbi.nlm.nih.gov/pubmed/26567759
J Nucl Med. 2015 Nov 12. pii: jnumed.115.167361. [Epub ahead of print]
First-in-man experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labelled pentixather in advanced stage multiple myeloma with extensive intra- and extramedullary disease.
Herrmann K1, Schottelius M2, Lapa C1, Osl T3, Poschenrieder A3, Haenscheid H1, Lueckerath K1, Schreder M1, Bluemel C1, Knott M1, Keller U3, Schirbel A1, Samnick S1, Lassmann M4, Kropf S5, Buck A1, Einsele H1, Wester HJ6, Knop S1.
http://www.ncbi.nlm.nih.gov/pubmed/26564323
Clin Cancer Res. 2015 Nov 11. [Epub ahead of print]
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Shah JJ1, Jakubowiak AJ2, O'Connor OA3, Orlowski RZ4, Harvey RD5, Smith MR6, Lebovic D7, Diefenbach C8, Kelly K9, Hua Z10, Berger AJ10, Mulligan G10, Faessel HM10, Tirrell S10, Dezube BJ10, Lonial S5.
http://www.ncbi.nlm.nih.gov/pubmed/26561559
Expert Rev Anticancer Ther. 2015 Nov 20. [Epub ahead of print]
Oral Ixazomib Maintenance Therapy in Multiple Myeloma.
Offidani M1, Corvatta L2, Gentili S1, Maracci L1, Leoni P1.
http://www.ncbi.nlm.nih.gov/pubmed/26588946
Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13799. [Epub ahead of print]
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E1,2, Gatt ME3, Rouvio O4, Ganzel C5, Chubar E6, Suriu C7, Tadmor T8, Shevetz O9, Lavi N10, Shochat T11, Cohen YC2,12, Avivi I2,12, Raanani P1,2, Magen H1,2.
http://www.ncbi.nlm.nih.gov/pubmed/26567759
J Nucl Med. 2015 Nov 12. pii: jnumed.115.167361. [Epub ahead of print]
First-in-man experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labelled pentixather in advanced stage multiple myeloma with extensive intra- and extramedullary disease.
Herrmann K1, Schottelius M2, Lapa C1, Osl T3, Poschenrieder A3, Haenscheid H1, Lueckerath K1, Schreder M1, Bluemel C1, Knott M1, Keller U3, Schirbel A1, Samnick S1, Lassmann M4, Kropf S5, Buck A1, Einsele H1, Wester HJ6, Knop S1.
http://www.ncbi.nlm.nih.gov/pubmed/26564323
Clin Cancer Res. 2015 Nov 11. [Epub ahead of print]
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Shah JJ1, Jakubowiak AJ2, O'Connor OA3, Orlowski RZ4, Harvey RD5, Smith MR6, Lebovic D7, Diefenbach C8, Kelly K9, Hua Z10, Berger AJ10, Mulligan G10, Faessel HM10, Tirrell S10, Dezube BJ10, Lonial S5.
http://www.ncbi.nlm.nih.gov/pubmed/26561559